Ibutamoren capsules contain MK-677, a potent, non-peptide growth hormone secretagogue receptor (GHS-R1a) agonist formulated for oral bioavailability in preclinical research models. In laboratory assays, ibutamoren mimics the endogenous action of ghrelin, triggering sustained, pulsatile release of somatotropin (GH) and subsequent elevations in insulin-like growth factor 1 (IGF-1) without disrupting basal cortisol levels.
Ibutamoren capsules contain MK-677, a potent, non-peptide growth hormone secretagogue receptor (GHS-R1a) agonist formulated for oral bioavailability in preclinical research models. In laboratory assays, ibutamoren mimics the endogenous action of ghrelin, triggering sustained, pulsatile release of somatotropin (GH) and subsequent elevations in insulin-like growth factor 1 (IGF-1) without disrupting basal cortisol levels.
In analytical biochemistry and preclinical pharmacology, ibutamoren capsules (frequently designated as MK-677 capsules) represent a primary non-peptide template for investigating the somatotropic axis. Unlike traditional peptide-based secretagogues that necessitate parenteral administration, ibutamoren is an orally active, long-acting agonist of the growth hormone secretagogue receptor (GHS-R1a). Preclinical models demonstrate that this compound selectively binds to GHS-R1a in the anterior pituitary and hypothalamus, replicating the signal transduction pathway normally initiated by endogenous ghrelin.
Researchers evaluating ibutamoren capsules target its unique ability to amplify endogenous growth hormone (GH) secretion while maintaining the natural pulsatile pattern of hormone release. Because the compound exhibits high oral bioavailability and a terminal elimination half-life of approximately 24 hours, it provides a stable in vitro and in vivo testing model for long-term somatotropic stimulation without requiring frequent administration protocols.
The molecular mechanism of ibutamoren centers on its high-affinity binding to GHS-R1a, a G-protein coupled receptor (GPCR). Binding activates the phospholipase C (PLC) signaling cascade, generating inositol trisphosphate (IP3) and diacylglycerol (DAG). This pathway triggers intracellular calcium mobilization and protein kinase C activation, culminating in the exocytosis of stored growth hormone from pituitary somatotropes. In vitro data indicate that this activation acts synergistically with endogenous growth hormone-releasing hormone (GHRH), amplifying natural secretory bursts.
A critical focus of research utilizing growth hormone secretagogues is the downstream activation of the hepatic axis. Following GHS-R1a stimulation, elevated circulating GH stimulates hepatic production of insulin-like growth factor 1 (IGF-1) and its primary binding protein, IGFBP-3. Preclinical studies suggest that ibutamoren maintains elevated serum IGF-1 concentrations over 24-hour periods, allowing investigators to observe long-term metabolic transcription downstream of the GH/IGF-1 axis.
When designing comparative research protocols for somatotropic axis modulation, investigators frequently compare oral non-peptide agonists against traditional peptide secretagogues. Compounds such as ipamorelin, cjc-1295-no-dac, and sermorelin exert distinct kinetic profiles compared to oral ibutamoren.
Injectable peptides typically display rapid receptor binding with short half-lives (ranging from 30 minutes to 2 hours), producing acute, sharp peaks in GH concentration. Conversely, ibutamoren capsules provide sustained GHS-R1a occupancy over an extended duration. Furthermore, while GHRH analogs like tesamorelin act via GHRH receptors, ibutamoren bypasses GHRH receptor dependency by directly targeting GHS-R1a. This structural divergence makes MK-677 an essential reference compound in comparative studies exploring receptor desensitization and feedback inhibition within the somatotropic pathway.
Rigorous scientific investigation requires reference materials that meet strict purity and identity metrics. Every batch of solid-form research compounds supplied by PX1 Research undergoes rigorous testing in ISO 17025 accredited analytical laboratories. We utilize Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) coupled with Electrospray Ionization Mass Spectrometry (ESI-MS) to verify chemical identity, purity thresholds exceeding 99%, and precise molecular mass.
To ensure experimental reproducibility across culture systems and animal models, PX1 Research provides a lot-specific Certificate of Analysis (COA) with every shipment. Our quality assurance protocol verifies minimal residual solvent levels, strict control over related substance impurities, and routine bacterial endotoxin testing (Chromogenic LAL method). Research institutions can review comprehensive analytical documentation across our entire catalog via the research library.
For laboratory researchers working with solid-dose ibutamoren preparations, proper analytical handling is critical for assay accuracy. When performing in vitro cell culture assays, solid contents must be extracted and solubilized in compatible organic solvents or buffered aqueous systems depending on the experimental setup. Ibutamoren mesylate demonstrates high solubility in dimethyl sulfoxide (DMSO), ethanol, and water.
To maintain chemical integrity, unopened solid-state capsules should be stored in desiccated conditions away from direct light at controlled temperatures (2°C to 8°C for short-term analytical storage, or -20°C for long-term storage). Reconstituted stock solutions intended for cell culture exposure or spectroscopic analysis should be aliquoted and frozen to prevent hydrolysis or thermal degradation over repeated freeze-thaw cycles. Detailed assay preparation methods are documented across our all research peptides reference material.
In rodent models and isolated tissue preparations, ibutamoren has been extensively studied to evaluate its effects on nitrogen balance, body composition, and skeletal tissue turnover. Preclinical studies suggest that chronic GHS-R1a activation by MK-677 reverses diet-induced nitrogen catabolism, demonstrating a pronounced protein-sparing effect under conditions of energy restriction.
Furthermore, animal assays assessing bone metabolism have documented increased markers of bone turnover, including osteocalcin and specific alkaline phosphatase isoenzymes. Because ibutamoren maintains GH pulsatility without causing sustained hypercortisolemia or significant alterations in basal prolactin, it serves as a valuable research model for isolating GH/IGF-1 actions from stress-axis pathways. Researchers interested in sourcing high-purity compounds for large-scale institutional projects can explore options through our wholesale portal.
Selecting verified reference standards is essential for maintaining integrity in scientific literature. PX1 Research manufactures all research compounds within GMP-compliant, USA-based facilities, adhering to strict quality management systems from raw material synthesis to final solid-state encapsulation.
Orders placed through PX1 Research are fulfilled rapidly with same-day dispatch (Monday through Friday) from our centralized logistics hubs in California and Arizona. Each shipment includes full lot traceability, tamper-evident packaging, and immediate access to digital COA files. This supply chain reliability ensures that laboratory workflows remain uninterrupted when conducting time-sensitive preclinical protocols.
What are ibutamoren capsules studied for in laboratory research?
Ibutamoren capsules (MK-677) are studied in preclinical research as an orally active growth hormone secretagogue. Laboratory investigations focus on its binding affinity for the GHS-R1a receptor, its ability to stimulate sustained pulsatile growth hormone (GH) release, and downstream elevations in serum IGF-1 concentrations.
How does ibutamoren differ from peptide secretagogues like ipamorelin?
Unlike peptide secretagogues such as ipamorelin or CJC-1295 which require liquid reconstitution and parenteral administration, ibutamoren is a non-peptide small molecule with high oral bioavailability and an extended half-life (~24 hours), enabling prolonged receptor activation.
What analytical testing is performed on PX1 Research ibutamoren capsules?
Every lot of ibutamoren undergoes testing in an ISO 17025 accredited laboratory using RP-HPLC for purity verification (>99%) and Mass Spectrometry (ESI-MS) for structural identity. Endotoxin testing via LAL assay is also conducted to ensure suitability for research environments.
Where can I find the Certificate of Analysis (COA) for my lot?
Lot-specific COAs detailing HPLC purity profiles, mass spectral data, and endotoxin levels are available directly on the PX1 Research website or by contacting technical support with your lot number.
What is the primary receptor target of ibutamoren?
Ibutamoren acts as a selective agonist at the growth hormone secretagogue receptor 1a (GHS-R1a), which is the endogenous receptor for the hunger-signaling peptide ghrelin.
How should solid-state ibutamoren capsules be stored in the lab?
Unopened capsule containers should be stored in a cool, dry environment away from light at controlled room temperature or refrigerated (2°C to 8°C). For long-term analytical storage of pure raw compound, -20°C in desiccated conditions is recommended.
What solvents are suitable for solubilizing ibutamoren for in vitro assays?
Ibutamoren mesylate is soluble in dimethyl sulfoxide (DMSO), ethanol, and sterile aqueous buffers (such as PBS). Solubilization limits should be tested according to specific assay parameters.
Does ibutamoren alter cortisol or prolactin levels in preclinical models?
Preclinical studies indicate that while ibutamoren causes modest transient increases in cortisol and prolactin upon initial administration, these levels generally remain within physiological ranges and return to baseline during sustained evaluation.
Where are PX1 Research compounds manufactured and shipped from?
All PX1 Research compounds are manufactured in US-based, GMP-compliant facilities and shipped directly from distribution hubs in California and Arizona with same-day processing for orders placed M–F before cutoff.
Are ibutamoren capsules intended for human consumption or clinical use?
No. Ibutamoren capsules supplied by PX1 Research are strictly for in vitro, animal, and laboratory research use only. They are not for human or veterinary consumption, therapy, or clinical applications.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.